

Induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy in patients with follicular lymphoma

GAUDI was a non-randomized trial

Untreated patients with follicular lymphoma allocated to one of the two induction chemotherapy backbones on a per-center basis

